Pharmacokinetics of satraplatin (JM216), an oral platinum(IV) complex under daily oral administration for 5 or 14 days

Anticancer Research

Volumn 23, Issue 3 C, 2003, Pages 2757-2765

  Vouillamoz Lorenz, Sylvie ^a   Buclin, Thierry ^b   Lejeune, Ferdy ^a   Bauer, Jean ^a   Leyvraz, Serge ^a   Decosterd, Laurent Arthur ^b  

^a Ctr Pluridisciplinaire d'Oncologie   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Anticancer chemotherapy; Atomic absorption spectrometry; JM216; Pharmacokinetics; Platinum complex

Indexed keywords

PLATINUM COMPLEX; SATRAPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BLOOD TOXICITY; BODY SURFACE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MALE; MULTIPLE DRUG DOSE; NEUTROPENIA; PARAMETER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; THROMBOCYTOPENIA; ULTRAFILTRATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PLATINUM;

EID: 0042624719     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ferrante K, Winograd B and Canetta R: Promising new developments in cancer chemotherapy. Cancer Chemother Pharmacol 43 (Suppl): S61-S68, 1999.
2. Harrap KR: Initiatives with platinum-and quinazoline-based antitumor molecules. Fourteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 55: 2761-2768, 1995.
3. McKeage MJ, Morgan SE, Boxall FE, Murrer BA, Hard GC and Harrap KR: Lack of nephrotoxicity of oral ammine/amine platinum(IV) dicarboxylate complexes in rodents. Brit J Cancer 67: 996-1000, 1993.
4. Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA and Harrap KR: Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res 53: 2581-2586, 1993.
5. Harrap KR, Murrer BA, Giandomenico C, Morgan SE, Kelland LR, Jones M, Goddard PM and Schurig J: Ammine/amine platinum IV dicarboxylates: a novel class of complexes which circumvent intrinsic cisplatin resistance. In: Platinum and Other Metal Coordination Complexes in Cancer Chemotherapy (Howell, S.B) Plenum New-York, pp 391-399, 1991.
6. McKeage MJ, Mistry P, Ward J, Boxall FE, Loh S, O'Neil C, Ellis P, Kelland LR, Morgan SE, Murrer B, Santabarbara P, Harrap KR and Judson IR: A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother & Pharmacol 36: 451-458, 1995.
7. McKeage MJ, Kelland LR, Boxall FE, Valenti MR, Jones M, Goddard PM, Gwynne J and Harrap KR: Schedule dependency of orally administered bis-acetato-amminedichloro-cyclohexylamine-platinum(IV) (JM216) in vivo. Cancer Res 54: 4118-4122, 1994.
8. McKeage MJ, Raynaud FI, Ward J, Berry C, O'Dell D, Kelland LR, Murrer BA, Santabarbara P, Harrap KR and Judson IR: Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 15: 2691-2700, 1997.
9. Kurata T, Tamura T, Sasaki Y, Fudjii H, Negoro S, Fukuoka M and Saijo N: Pharmacokinetic and pharmacodynamic analysis of bis-aceto-ammine-dichloro-cyclohexylamine-platinum (IV) (JM216) administered once a day for five consecutive days: a phase I study. Jap J Clin Oncol 30: 377-384, 2000.
10. Judson IR, Cerny T, Epelbaum R, Dunlop D, Smyth J, Schaefer B, Roelvink M, Kaplan S and Hanauske A: Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation. Ann Oncol 8: 604-606, 1997.
11. Fokkema E, Groen HJM, Bauer J, Uges DRA, Weil C and Smith IE: Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol 17: 3822-3827, 1999.
12. Fokkema E, de Vries EGE, Meijer S and Groen HJM: Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients. Cancer Chemother Pharmacol 45: 89-92, 2000.
13. Amorino GP, Mohr PJ, Hercules SK, Pyo H and Choy H: Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy. Cancer Chemother Pharmacol 46: 423-426, 2000.
14. Georges CM, Haraf DJ, Mauer AM, Krauss SA, Hoffman PC, Rudin CM, Szeto L and Vokes EE: A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest. Investig New Drugs 19: 303-310, 2001
15. Sessa C, Minoia C, Ronchi A, Zucchetti M, Bauer J, Borner M, de Jong J, Pagani O, Renard J, Weil C and d'Incalci M: Phase I clinical and pharmacokinetic study of the oral platinum analogue (JM216) given daily for 14 days. Ann Oncol 9: 1315-22, 1998.
16. Vouillamoz-Lorenz S, Bauer J, Lejeune F and Decosterd LA : Validation of an atomic absorption spectrophotometric method for the determination of platinum in biological fluids from patients receiving the oral platinum derivative JM216. J Pharm Biomed Anal 25: 465-475, 2001.
17. Raynaud FI, Mistry P, Donaghue A, Poon GK, Kelland LR, Barnard CJF, Murrer BA and Harrap KR: Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother Pharmacol 38: 155-162, 1996.
18. Lévi F, Metzger G, Massari C and Milano G: Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 38: 1-21, 1999.
19. Schierl R, Rohrer B and Hohnloser J: Long-term platinum excretion in patients treated with cisplatin. Cancer Chemother Pharmacol 36: 75-8, 1995.
20. Bonetti A, Franceschi T, Apostoli P, Messori A, Sperotto L, Cetto GL, Molino A and Leone R: Cisplatin pharmacokinetics using a five-day schedule during repeated courses of chemotherapy in germ cell tumors. Ther Drug Monitor 17: 25-32, 1995.
21. Van der Vijgh WJF: Clinical pharmacokinetics of carboplatinum. Clin Pharmacokinet 21: 242-261, 1991.
22. Raynaud FI, McKeage MJ, Ward J, Berry C, Odell D, Murrer BA, Santabarbara P, Judson IR and Harrap KR: Pharmacokinetic study of orally administered ammine diacetatodichloro(cyclohexylamine)platinum IV (JM216) in a 5-day dose schedule phase I clinical trial. In: Novel Approaches in Anticancer Drug Design. Molecular Modelling - New Treatment Strategies (Zeller WJ, D'Incalci M, Newell DR, Editors). Contrib Oncol, Krager, Basel, pp 100-108, 1995.
23. Kelland LR: An update on satraplatin: the first orally available platinum anticancer drug. Exp Opin Invest Drugs 9: 1354-1384, 2000.
24. Ando Y, Shimizu T, Nakamura K, Mushiroda T, Nakagawa T, Kodama T and Kamataki T: Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent. Brit J Cancer 78: 1170-1174, 1998.